Burning Rock (NASDAQ: BNR) announced that founder, chairman and CEO Yusheng Han purchased 31,487 ADSs on April 2, 2026 for US$546,603.90 from the open market.
Combined with 41,246 ADSs bought in the prior post-earnings window, Mr. Han has acquired an aggregate of 72,733 ADSs for US$1,358,325.18 across two consecutive post-earnings windows, and may continue purchasing in compliance with applicable rules.
Loading...
Loading translation...
Positive
Founder and CEO purchased 31,487 ADSs on April 2, 2026 for US$546,603.90
Aggregate insider purchases of 72,733 ADSs totaling US$1,358,325.18 across two post-earnings windows
Purchases conducted in compliance with applicable rules and the company insider trading policy
Negative
None.
News Market Reaction – BNR
-0.61%
2 alerts
-0.61%Session close to close
$183.57MMarket Cap
0.1xRel. Volume
In the Apr 2 session, BNR declined 0.61%, reflecting a mild negative market reaction.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
This announcement highlights continued open‑market ADS purchases by the founder and CEO, totaling 72...
Analysis
This announcement highlights continued open‑market ADS purchases by the founder and CEO, totaling 72,733 ADSs for US$1,358,325.18 across two post‑earnings windows. Historically, similar insider buying on Jan 5, 2026 coincided with a strong positive move, while earnings and AGM‑related news often saw weaker reactions. Investors may watch for further purchase disclosures, upcoming financial updates, and any changes in trading activity versus the 200‑day trend.
Key Figures
ADSs purchased (Apr 2026):31,487 ADSsPurchase value (Apr 2026):US$546,603.90Prior ADS purchases:41,246 ADSs+2 more
5 metrics
ADSs purchased (Apr 2026)31,487 ADSsFounder open‑market purchase on April 2, 2026
Purchase value (Apr 2026)US$546,603.90Cost of 31,487 ADSs bought by founder
Prior ADS purchases41,246 ADSsBought in last post‑earnings trading window
Total ADSs purchased72,733 ADSsAggregate across two post‑earnings windows
Total purchase valueUS$1,358,325.18Aggregate consideration for 72,733 ADSs
Q3 2025 results showed revenue growth, margin expansion and narrower net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, including earnings and governance items, often saw negative or muted price reactions even when fundamentals or corporate actions looked constructive. The prior founder purchase announcement was a notable exception, drawing a strong positive move.
Recent Company History
Over the last six months, Burning Rock reported improving financials, with Q3 2025 and full‑year 2025 results showing higher revenue, expanding gross margins and sharply lower operating expenses and net loss. Nonetheless, shares traded down after both earnings releases. Corporate governance news around the 2025 AGM also coincided with declines. By contrast, the Jan 5, 2026 announcement of the founder’s ADS purchases led to a strong 24.39% gain, providing the closest historical parallel to today’s additional insider buying.
Key Terms
ads, next generation sequencing, ngs, precision oncology, +2 more
6 terms
adsfinancial
"has purchased 31,487 of the Company’s ADSs for US$546,603.90"
Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.
next generation sequencingmedical
"application of next generation sequencing (NGS) technology in the field"
A collection of advanced laboratory methods that read and map large amounts of DNA or RNA quickly and at lower cost than older techniques; think of it as scanning thousands of pages of a book at once instead of reading one page at a time. Investors care because it accelerates drug development, enables precise diagnostics and personalized treatments, and can create recurring revenue from tests, instruments, and data services as adoption expands.
ngsmedical
"next generation sequencing (NGS) technology in the field of precision"
A laboratory method that reads large amounts of DNA or RNA quickly to identify genetic differences, mutations, or microbes, similar to scanning many pages of a book at once to find important words. Investors care because it drives diagnostics, drug discovery and personalized treatments, can create recurring revenue from testing services and instruments, and influences regulatory approvals, partnerships and market value in biotech and healthcare companies.
precision oncologymedical
"technology in the field of precision oncology, today announced that"
Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.
rule 10b-18regulatory
"including the requirements under Rule 10b-18 and Rule 10b5-1 of"
Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.
rule 10b5-1regulatory
"requirements under Rule 10b-18 and Rule 10b5-1 of the Securities"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 31,487 of the Company’s ADSs for US$546,603.90 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 41,246 ADSs purchased in the last post-earnings trading window, Mr. Han has purchased an aggregate of 72,733 of the Company’s ADSs for US$1,358,325.18 across two consecutive post-earnings trading windows, indicating his confidence in the Company’s business and prospect.
Mr. Han may continue to purchase the Company’s ADSs through open-market transactions, privately negotiated transactions or block trades, or other legally permissible means, depending on market conditions and in accordance with the applicable rules and regulations. The timing and conditions of Mr. Han’s purchase will be subject to various factors, including the requirements under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as well as the Company’s insider trading policy.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Contact: IR@brbiotech.com
FAQ
How many ADSs did Yusheng Han buy on April 2, 2026 for Burning Rock (BNR)?
He bought 31,487 ADSs for US$546,603.90 on April 2, 2026. According to the company, the purchase was made on the open market and complied with applicable rules and the insider trading policy.
What is the total amount of ADSs Yusheng Han purchased across the two post-earnings windows for BNR?
He purchased an aggregate of 72,733 ADSs totaling US$1,358,325.18 across two post-earnings windows. According to the company, this combines the April 2, 2026 trades with prior post-earnings purchases.
Will Yusheng Han continue buying Burning Rock (BNR) ADSs after April 2, 2026?
He may continue purchasing ADSs through open-market or other legally permissible means. According to the company, future purchases will follow Rule 10b-18, Rule 10b5-1 and the insider trading policy.
Did Burning Rock state that Yusheng Han purchased ADSs in compliance with regulations for BNR?
Yes, the company said the April 2, 2026 purchase was conducted in compliance with applicable rules and the insider trading policy. According to the company, the trades adhered to relevant securities rules.
What might Yusheng Han's purchases signal to investors about Burning Rock (BNR)?
Insider purchases can signal management confidence but are not guarantees of future performance. According to the company, Mr. Han's consecutive post-earnings purchases indicate his confidence in the company's business and prospects.
